Actelion
Clinical trials sponsored by Actelion, explained in plain language.
-
New hope for kids with rare lung condition: drug shows promise in major trial
Disease control CompletedThis study tested a drug called macitentan in 165 children with pulmonary arterial hypertension (PAH), a serious condition where blood pressure in the lungs is too high. The goal was to see how the drug works in the body, if it is safe, and if it helps control the disease better …
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 17, 2026 07:03 UTC
-
New hope for rare lung condition: experimental drug shows promise
Disease control CompletedThis study tested an experimental drug called ACT-293987 in 43 adults with pulmonary arterial hypertension (PAH), a serious condition where high blood pressure damages the arteries in the lungs. Participants first received a single dose to measure immediate effects on blood flow,…
Phase: PHASE2 • Sponsor: Actelion • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
New PAH pill shows promise in delaying disease worsening
Disease control CompletedThis study tested a drug called selexipag in over 1,100 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. The goal was to see if selexipag could delay the first time a patient's condition got worse or led to death, compared…
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
One pill to rule them all? new combo therapy for PAH shows promise
Disease control CompletedThis study tested a single pill combining two drugs (macitentan and tadalafil) for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. 187 adults with PAH took either the combination pill or one of the two drugs alone for 16 …
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 15, 2026 11:55 UTC